Axon Enterprise, Inc. Free cash flow decreased by 135.2% to -$54.64M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 5962.9%, from $932.00K to -$54.64M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows relatively stable performance with a 0.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $20.67M | $3.98M | $0.00 | $26.87M | $6.63M | $26.53M | $119.54M | -$64.84M | $29.52M | $48.92M | $116.03M | -$32.13M | $71.45M | $64.85M | $225.37M | $932.00K | -$114.66M | $33.38M | $155.43M | -$54.64M |
| QoQ Change | — | -80.7% | -100.0% | — | -75.3% | +300.3% | +350.6% | -154.2% | +145.5% | +65.7% | +137.2% | -127.7% | +322.3% | -9.2% | +247.5% | -99.6% | <-999% | +129.1% | +365.6% | -135.2% |
| YoY Change | — | — | — | — | -67.9% | +566.8% | — | -341.3% | +345.4% | +84.4% | -2.9% | +50.4% | +142.0% | +32.6% | +94.2% | +102.9% | -260.5% | -48.5% | -31.0% | <-999% |